Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Ophthalmol. 2009 Jul;93(7):887-90. doi: 10.1136/bjo.2008.142679. Epub 2008 Aug 14.

The success of primary chemotherapy for group D heritable retinoblastoma.

Author information

1
St Bartholomew's and the Royal London Hospital, West Smithfield, London EC1A 7BE, UK. victoria.lendrum@gmail.com

Abstract

AIMS:

To report the ocular survival and event-free survival following primary multiagent chemotherapy for group D, heritable bilateral retinoblastoma (RB).

METHODS:

The RB database was used to identify children with heritable, bilateral RB treated with primary chemotherapy (six cycles of vincristine, etoposide and carboplatin). Only Group D eyes with more than 12 months' follow-up were analysed. The timing, number and type of salvage treatments were recorded. Kaplan-Meier estimates for the ocular survival and event-free survival (percentage of eyes that avoided external beam radiotherapy and/or enucleation) were performed as a function of time.

RESULTS:

Of 18 group D eyes, two (11%) were treated successfully with chemotherapy alone, nine (50%) underwent successful salvage treatment, and seven (39%) were enucleated. The median time from completing chemotherapy to enucleation was 9 months (range 4 to 25 months). Ocular survival was 67% at 2 years. External beam radiotherapy proved successful salvage treatment in five of nine eyes, so the event-free survival was 34% at 2 years.

CONCLUSION:

Multiagent chemotherapy alone is rarely sufficient for the preservation of group D eyes. External beam radiotherapy and plaque radiotherapy remain important salvage treatments for advanced, heritable retinoblastoma.

PMID:
18703556
DOI:
10.1136/bjo.2008.142679
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center